about
Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.Safety and tolerability of transcranial direct current stimulation to stroke patients - A phase I current escalation study.Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.The role of fMRI in drug development.A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.What evidence is used to underpin the design of strength-based exercise interventions evaluated in randomised controlled trials for rheumatoid arthritis? A systematic review protocol
P2860
Q37592456-36087B7E-34E3-49AB-ACD7-FFF423CDE7DEQ38379638-C26FB84C-D641-4028-8A87-1FBD18DE32B2Q47135344-C3CA7739-BEE0-4354-AEE2-83E5349C800FQ49873690-6265BB60-90CD-427D-BBC5-AAB30F018B4CQ50246047-09D7F8D2-6AB7-4F4C-A6AE-60EF8BDCE161Q55040314-B40C8576-CAF7-406C-AFD1-9581C35D81F9Q58753933-B0A9BEAE-CE76-4831-BA36-35F60FD46BA2
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Phase 1 trial design: is 3 + 3 the best?
@en
type
label
Phase 1 trial design: is 3 + 3 the best?
@en
prefLabel
Phase 1 trial design: is 3 + 3 the best?
@en
P2093
P2860
P1433
P1476
Phase 1 trial design: is 3 + 3 the best?
@en
P2093
Aaron R Hansen
Donna M Graham
Gregory R Pond
Lillian L Siu
P2860
P304
P356
10.1177/107327481402100304
P577
2014-07-01T00:00:00Z